Polianta Ltd Acquires New Stake in Icon Plc $ICLR

Polianta Ltd bought a new stake in Icon Plc (NASDAQ:ICLR) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 10,800 shares of the medical research company’s stock, valued at approximately $1,876,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ICLR. EFG International AG purchased a new stake in shares of Icon during the fourth quarter worth about $27,000. Abound Financial LLC acquired a new stake in Icon during the fourth quarter worth approximately $54,000. GAMMA Investing LLC boosted its position in Icon by 21.4% during the second quarter. GAMMA Investing LLC now owns 391 shares of the medical research company’s stock worth $68,000 after acquiring an additional 69 shares during the last quarter. Johnson Financial Group Inc. acquired a new position in Icon in the 3rd quarter valued at $71,000. Finally, Blue Trust Inc. grew its position in shares of Icon by 207.5% in the first quarter. Blue Trust Inc. now owns 658 shares of the medical research company’s stock valued at $73,000 after purchasing an additional 444 shares during the period. 95.61% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on ICLR shares. DA Davidson set a $164.00 price objective on shares of Icon in a research note on Monday, June 1st. Mizuho raised their target price on shares of Icon from $180.00 to $190.00 and gave the stock an “outperform” rating in a research report on Friday, June 26th. Weiss Ratings lowered shares of Icon from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, May 29th. UBS Group set a $160.00 price target on shares of Icon in a research note on Wednesday, June 24th. Finally, Citigroup lifted their price target on shares of Icon from $165.00 to $180.00 and gave the company a “neutral” rating in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Icon currently has a consensus rating of “Hold” and a consensus target price of $170.40.

Icon Stock Up 2.1%

Shares of NASDAQ:ICLR opened at $164.51 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.95 and a current ratio of 0.95. Icon Plc has a 1 year low of $66.57 and a 1 year high of $203.91. The stock has a market capitalization of $12.60 billion, a P/E ratio of 38.62, a PEG ratio of 6.82 and a beta of 1.21. The stock has a 50-day simple moving average of $160.35 and a 200-day simple moving average of $134.86.

Icon (NASDAQ:ICLR) last posted its quarterly earnings results on Thursday, July 30th. The medical research company reported $2.56 EPS for the quarter, beating the consensus estimate of $2.55 by $0.01. Icon had a net margin of 3.99% and a return on equity of 8.02%. The firm had revenue of $2.06 billion for the quarter, compared to analyst estimates of $2 billion. During the same quarter last year, the firm posted $3.26 earnings per share. Icon’s revenue for the quarter was up 2.3% compared to the same quarter last year. Equities analysts forecast that Icon Plc will post 9.57 earnings per share for the current year.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.